Exhibit 99.1


Hemispherx Biopharma Appoints McGladrey & Pullen as Independent Auditing Firm
Thursday November 9, 8:30 am ET


PHILADELPHIA--(BUSINESS  WIRE)--Hemispherx  Biopharma,  Inc. (AMEX:  HEB - News)
announced that its Board of Directors has engaged McGladrey & Pullen, LLP as the
Company's new independent registered public accounting firm following the filing
of its quarterly report on Form 10-Q for the period ended September 30, 2006.

McGladrey & Pullen, a partner-owned CPA firm, provides audit and attest services
to  midsized  companies.  It has 100 offices in the United  States.  McGladrey &
Pullen helps clients with global  business  needs through its  membership in RSM
International  (an  affiliation  of  separate  and  independent  accounting  and
consulting firms).

McGladrey & Pullen LLP and RSM  McGladrey  Inc., a business  services  provider,
have an alternative  practice  structure.  Though separate and independent legal
entities,  they work together to serve clients'  business needs. When considered
together,  the two companies rank as the  fifth-largest  provider of accounting,
tax and business  consulting in the United  States  (source:  Public  Accounting
Report). Web site: http://www.mcgladrey.com/.

About Hemispherx Biopharma

Hemispherx  Biopharma,  Inc.  is a  biopharmaceutical  company  engaged  in  the
manufacture  and clinical  development  of new drug  entities  for  treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(R)  and the  experimental  therapeutics  Ampligen(R) and Oragens(R).
Alferon  N  Injection(R)  is  approved  for a  category  of STD  infection,  and
Ampligen(R)  and  Oragens(R)  represent  experimental  RNA  nucleic  acids being
developed  for globally  important  viral  diseases and  disorders of the immune
system.   Hemispherx's  platform  technology  includes  large  and  small  agent
components for potential  treatment of various  severely  debilitating  and life
threatening  diseases.  Hemispherx  has in excess of 100 patents  comprising its
core  intellectual  property estate, a fully  commercialized  product (Alferon N
Injection(R))  and GMP certified  manufacturing  facilities for its novel pharma
products. For more information please visit www.hemispherx.net.

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications.

Contact:
Hemispherx Biopharma, Inc.
Dianne Will, 518-398-6222
ir@hemispherx.net
or
CCG Investor Relations
Sean Collins, Sr. Partner, 310-477-9800